LW-02 Column Instructions for Use

This information is intended for healthcare providers practicing in the EU only.

Immunicom’s LW-02 Column has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. Immunicom’s Immunopheresis® therapy, including the LW-02 Column, has not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or treatments with your doctor.

Last Updated: March 16, 2023